The muscarinic M
Adult
Association Learning
/ drug effects
Brain
/ drug effects
Brain Mapping
Cholinergic Agents
/ therapeutic use
Female
Humans
Magnetic Resonance Imaging
/ methods
Male
Memory
/ drug effects
Neuropsychological Tests
Psychotic Disorders
/ drug therapy
Receptor, Muscarinic M1
/ drug effects
Young Adult
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
10
2019
revised:
22
04
2020
accepted:
22
04
2020
pubmed:
21
6
2020
medline:
30
3
2021
entrez:
21
6
2020
Statut:
ppublish
Résumé
Psychotic disorders are characterized by prominent deficits in associative learning and memory for which there are currently no effective treatments. Functional magnetic resonance imaging (fMRI) studies in psychotic disorders have identified deficits in fronto-temporal activation during associative learning and memory. The underlying pathology of these findings remains unclear. Postmortem data have suggested these deficits may be related to loss of muscarinic M Twenty-six medication-free subjects diagnosed with a psychotic disorder and 29 age-, gender-, and IQ-matched healthy controls underwent two functional magnetic resonance imaging (fMRI) sessions, one under placebo and one under selective M In the subjects with psychotic disorders DLPFC hypoactivation was only found in the memory phase of the task. In both learning and memory phases of the task, M The current study is the first to show differences in M
Sections du résumé
BACKGROUND
Psychotic disorders are characterized by prominent deficits in associative learning and memory for which there are currently no effective treatments. Functional magnetic resonance imaging (fMRI) studies in psychotic disorders have identified deficits in fronto-temporal activation during associative learning and memory. The underlying pathology of these findings remains unclear. Postmortem data have suggested these deficits may be related to loss of muscarinic M
METHODS
Twenty-six medication-free subjects diagnosed with a psychotic disorder and 29 age-, gender-, and IQ-matched healthy controls underwent two functional magnetic resonance imaging (fMRI) sessions, one under placebo and one under selective M
RESULTS
In the subjects with psychotic disorders DLPFC hypoactivation was only found in the memory phase of the task. In both learning and memory phases of the task, M
CONCLUSION
The current study is the first to show differences in M
Identifiants
pubmed: 32563036
pii: S2213-1582(20)30115-7
doi: 10.1016/j.nicl.2020.102278
pmc: PMC7305431
pii:
doi:
Substances chimiques
Cholinergic Agents
0
Receptor, Muscarinic M1
0
Banques de données
NTR
['NTR5094']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102278Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Schizophr Res. 2004 Dec 15;72(1):41-51
pubmed: 15531406
Neuroimage Clin. 2018 Mar 03;18:713-719
pubmed: 29560312
Hippocampus. 2017 Jul;27(7):794-810
pubmed: 28422371
Trends Cogn Sci. 2012 Jan;16(1):27-34
pubmed: 22169777
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
World Psychiatry. 2014 Oct;13(3):224-32
pubmed: 25273286
Trends Pharmacol Sci. 2011 Sep;32(9):507-13
pubmed: 21700346
Neuropsychologia. 2011 Jun;49(7):2060-70
pubmed: 21477602
Am J Psychiatry. 2008 Aug;165(8):1033-9
pubmed: 18593778
Psychol Med. 2005 Jul;35(7):1031-41
pubmed: 16045069
Front Psychiatry. 2018 Dec 05;9:622
pubmed: 30568606
Exp Brain Res. 1995;104(2):337-48
pubmed: 7672026
Mol Psychiatry. 2018 Aug;23(8):1764-1772
pubmed: 29311665
Psychopharmacology (Berl). 2001 Jun;156(1):53-7
pubmed: 11465633
EJNMMI Phys. 2018 Mar 1;5(1):4
pubmed: 29492787
J Chem Neuroanat. 2003 Dec;26(4):233-42
pubmed: 14729126
Brain Res. 1999 Jul 10;834(1-2):6-12
pubmed: 10407088
Drug Discov Today. 2019 Dec;24(12):2307-2314
pubmed: 31499186
Handb Clin Neurol. 2013;116:693-737
pubmed: 24112934
Philos Trans R Soc Lond B Biol Sci. 2013 Dec 02;369(1633):20130288
pubmed: 24298167
Schizophr Bull. 2010 May;36(3):465-71
pubmed: 20154201
Psychopharmacology (Berl). 2011 Jun;215(3):549-66
pubmed: 21336581
Mol Psychiatry. 2002;7(10):1083-91
pubmed: 12476323
Nat Neurosci. 2003 Jan;6(1):51-8
pubmed: 12483218
Trends Neurosci. 2019 Mar;42(3):205-220
pubmed: 30621912
Ind Psychiatry J. 2016 Jul-Dec;25(2):135-144
pubmed: 28659691
Cureus. 2017 Dec 20;9(12):e1973
pubmed: 29492362
J Neurosci. 1991 Oct;11(10):3218-26
pubmed: 1941081
J Nucl Med. 2015 Feb;56(2):317-22
pubmed: 25593117
Neurosci Biobehav Rev. 2015 Aug;55:393-402
pubmed: 26003527
Neuropsychol Rev. 2018 Dec;28(4):509-533
pubmed: 30343458
Neuropharmacology. 2018 Jan;128:492-502
pubmed: 28729220
Am J Psychiatry. 2004 Jun;161(6):1004-15
pubmed: 15169688
Behav Sci (Basel). 2013 Jun 27;3(3):330-47
pubmed: 25379242
Neuroimage. 2012 Jan 16;59(2):1719-26
pubmed: 21907293
Am J Psychiatry. 2009 Aug;166(8):863-74
pubmed: 19411370
Drug Discov Today. 2013 Dec;18(23-24):1185-99
pubmed: 24051397
Eur J Clin Pharmacol. 1986;29(6):735-7
pubmed: 3709619
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13674-9
pubmed: 14595031
Front Cell Neurosci. 2013 May 03;7:55
pubmed: 23653591
Arch Gen Psychiatry. 2007 Jan;64(1):19-28
pubmed: 17199051
Curr Protoc Neurosci. 2013;Chapter 9:Unit9.43
pubmed: 23559309
Front Pharmacol. 2014 Dec 15;5:277
pubmed: 25566074
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223